Javascript must be enabled to continue!
The incremental value of tuberculosis detecting African giant pouched rats over Smear microscopy and Xpert MTB/RIF for Tanzanian TB detection
View through CrossRef
Background
Prior studies that used Anti-Persoonsmijnen Ontmijnende Product Ontwikkeling (APOPO)-trained African giant pouched rats reported an annual average of 40% increase in sputum-smear-positive tuberculosis (TB) detection. Sputum-smear microscopy (smear) is being replaced by Xpert MTB/RIF (Xpert)-based diagnostic algorithms in many countries. We evaluated the incremental values of rat-based case detection over smear and Xpert.
Methods
From January to December 2023, sputum samples were collected from presumptive TB patients at 69 health facilities that use Xpert or smear-based diagnostic algorithms. An average of five rats were used at APOPO to re-evaluate the second sample from Xpert-negative patients and the smear-negative sample. Concentrated smears and Ziehl-Neelsen staining were used to confirm samples that were rat-positive (samples indicated positive by ≥ 1 rat). We analyzed the increase in case detection (incremental yield) by the rats over smear and Xpert and compared the rise against Mycobacterium bacillary load using the Chi-square test.
Results
A total of 43,153 samples from 34,565 patients were collected and re-evaluated by rats. There were 6,717 bacteriologically confirmed TB cases; 4,541 (68%) of these cases were detected at health facilities (3,239 from Xpert and 1,302 from smear sites); the remaining 2,176 (32%) were found by trained rats, representing 48% (2,176/4,541) overall incremental value. Of which, 65% (1,409/2,176) and 35% (767/2,176) were among Xpert and smear-negative patients, respectively. The Incremental yield by rats at Xpert facilities was 44% (1,409/3,239), while it was 59% (767/1,302) at smear facilities, Odds Ratio, OR = 0.74, 95% confidence interval, CI:0.66–0.82. The rats were 47% more likely to identify TB among Acid Fast Bacilli smear 1 + or scanty from Xpert-negative samples than smear-negative [91% (1,276/1,409) versus 87% (665/767), OR = 1.47, 95% CI:1.12–1.94]. The difference between children and adults, however, was not substantial, [69% (68/98) versus 67% (1,138/1,701), OR = 1.12, 95% CI:0.72–1.74].
Conclusions
Our finding indicated that trained rats reasonably added benefit over DOT TB case findings. According to our data, switching from smear to Xpert sites lowered the added value by more than a quarter, even though the Xpert sites were likely to benefit more case finding among TB patients with lower bacillary loads.
Public Library of Science (PLoS)
Title: The incremental value of tuberculosis detecting African giant pouched rats over Smear microscopy and Xpert MTB/RIF for Tanzanian TB detection
Description:
Background
Prior studies that used Anti-Persoonsmijnen Ontmijnende Product Ontwikkeling (APOPO)-trained African giant pouched rats reported an annual average of 40% increase in sputum-smear-positive tuberculosis (TB) detection.
Sputum-smear microscopy (smear) is being replaced by Xpert MTB/RIF (Xpert)-based diagnostic algorithms in many countries.
We evaluated the incremental values of rat-based case detection over smear and Xpert.
Methods
From January to December 2023, sputum samples were collected from presumptive TB patients at 69 health facilities that use Xpert or smear-based diagnostic algorithms.
An average of five rats were used at APOPO to re-evaluate the second sample from Xpert-negative patients and the smear-negative sample.
Concentrated smears and Ziehl-Neelsen staining were used to confirm samples that were rat-positive (samples indicated positive by ≥ 1 rat).
We analyzed the increase in case detection (incremental yield) by the rats over smear and Xpert and compared the rise against Mycobacterium bacillary load using the Chi-square test.
Results
A total of 43,153 samples from 34,565 patients were collected and re-evaluated by rats.
There were 6,717 bacteriologically confirmed TB cases; 4,541 (68%) of these cases were detected at health facilities (3,239 from Xpert and 1,302 from smear sites); the remaining 2,176 (32%) were found by trained rats, representing 48% (2,176/4,541) overall incremental value.
Of which, 65% (1,409/2,176) and 35% (767/2,176) were among Xpert and smear-negative patients, respectively.
The Incremental yield by rats at Xpert facilities was 44% (1,409/3,239), while it was 59% (767/1,302) at smear facilities, Odds Ratio, OR = 0.
74, 95% confidence interval, CI:0.
66–0.
82.
The rats were 47% more likely to identify TB among Acid Fast Bacilli smear 1 + or scanty from Xpert-negative samples than smear-negative [91% (1,276/1,409) versus 87% (665/767), OR = 1.
47, 95% CI:1.
12–1.
94].
The difference between children and adults, however, was not substantial, [69% (68/98) versus 67% (1,138/1,701), OR = 1.
12, 95% CI:0.
72–1.
74].
Conclusions
Our finding indicated that trained rats reasonably added benefit over DOT TB case findings.
According to our data, switching from smear to Xpert sites lowered the added value by more than a quarter, even though the Xpert sites were likely to benefit more case finding among TB patients with lower bacillary loads.
Related Results
Evaluasi sensitivitas dan spesifisitas Xpert MTB RIF dan Xpert MTB RIF Ultra pada berbagai spesimen untuk mendiagnosis tuberkulosis ekstra paru: Sebuah telaah literatur sistematis
Evaluasi sensitivitas dan spesifisitas Xpert MTB RIF dan Xpert MTB RIF Ultra pada berbagai spesimen untuk mendiagnosis tuberkulosis ekstra paru: Sebuah telaah literatur sistematis
Background: Molecular examination using Xpert MTB RIF and Xpert MTB RIF Ultra was introduced by WHO in 2010 as a fast and practical supporting examination in detecting Mycobacteriu...
Comparison of tests done, and Tuberculosis cases detected by Xpert® MTB/RIF and Xpert® MTB/RIF-Ultra in Uganda
Comparison of tests done, and Tuberculosis cases detected by Xpert® MTB/RIF and Xpert® MTB/RIF-Ultra in Uganda
Abstract
Background
Uganda introduced Xpert® MTB/RIF assay into its TB diagnostic algorithm in January 2012. In July 2018, this...
Comparison evaluation between gene Xpert Mtb/Rif and multiplex PCR for rapid diagnosis of mycobacterium tuberculosis
Comparison evaluation between gene Xpert Mtb/Rif and multiplex PCR for rapid diagnosis of mycobacterium tuberculosis
Abstract
Objective: To evaluate Gene Xpert MTB/RIF and Multiplex PCRfor detection of Mycobacterium tuberculosis and Rifampicin resistance comparing with gold standard MGIT 96...
The Value of Lateral Flow Urine Lipoarabinomannan Assay and Empirical Treatment in the Xpert MTB/RIF Ultra Era: a Prospective Cohort Study
The Value of Lateral Flow Urine Lipoarabinomannan Assay and Empirical Treatment in the Xpert MTB/RIF Ultra Era: a Prospective Cohort Study
Abstract
Introduction: The value of Lateral Flow urine Lipoarabinomannan (LF-LAM) assay and the role of empiric tuberculosis (TB) treatment in the era of the highly sensiti...
Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia
Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia
Abstract
Background
The main advantage of GeneXpert MTB/RIF® (Xpert) molecular diagnostic technology is the rapid detection of M.tuberculosis DNA and mutations associated with rifa...
Survival and infectivity of mycobacterium tuberculosis after aerosolization
Survival and infectivity of mycobacterium tuberculosis after aerosolization
<p dir="ltr">Tuberculosis (TB) remains the leading cause of death by a single infectious organism with over 1.3 million people succumbing to the disease every year. Despite e...
Effect of sputum quality and role of Xpert® MTB/RIF assay for detection of smear-negative pulmonary tuberculosis in same-day diagnosis strategy in Addis Ababa, Ethiopia
Effect of sputum quality and role of Xpert® MTB/RIF assay for detection of smear-negative pulmonary tuberculosis in same-day diagnosis strategy in Addis Ababa, Ethiopia
Background: There is limited information on the performance of the Xpert® MTB/RIF test for diagnosis of smear-negative pulmonary tuberculosis (SNPT) and rifampicin resistance (RR) ...
The value of lateral flow urine lipoarabinomannan assay and empirical treatment in Xpert MTB/RIF ultra negative patients with presumptive TB: a prospective cohort study
The value of lateral flow urine lipoarabinomannan assay and empirical treatment in Xpert MTB/RIF ultra negative patients with presumptive TB: a prospective cohort study
AbstractThe value of Lateral Flow urine Lipoarabinomannan (LF-LAM) assay and the role of empiric tuberculosis (TB) treatment in the era of the highly sensitive Xpert MTB/RIF Ultra ...

